Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 3849

Sort by

Sort Order Select

Journal Articles

How I incorporate novel agents into the treatment of classical Hodgkin lymphoma

Narendranath Epperla, Alex F. Herrera

Blood (2021) 138 (7): 520–530.

https://doi.org/10.1182/blood.2020007900

Published: 2021

Journal Articles

Mutational landscape of gray zone lymphoma

Blood (2021) 137 (13): 1765–1776.

https://doi.org/10.1182/blood.2020007507

Published: 2021

Includes: Supplemental data

Journal Articles

Protect our children: Hodgkin lymphoma survivors

Nancy L. Bartlett

Blood (2021) 137 (11): 1433–1434.

https://doi.org/10.1182/blood.2020010320

Published: 2021

Journal Articles

Subsequent neoplasms in pediatric Hodgkin lymphoma

Blood (2021) 137 (11): 1562.

https://doi.org/10.1182/blood.2021011303

Published: 2021

Journal Articles

Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children’s Oncology Group

Lisa Giulino-Roth, Qinglin Pei, Allen Buxton, Rizvan Bush, Yue Wu, Suzanne L. Wolden, Louis S. Constine, Kara M. Kelly, Cindy L. Schwartz, Debra L. Friedman

Blood (2021) 137 (11): 1449–1456.

https://doi.org/10.1182/blood.2020007225

Published: 2021

Includes: Supplemental data

Journal Articles

PD-1 blockade for untreated Hodgkin lymphoma

Alison J. Moskowitz

Blood (2021) 137 (10): 1271–1272.

https://doi.org/10.1182/blood.2020009281

Published: 2021

Journal Articles

Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma

Pamela B. Allen, Hatice Savas, Andrew M. Evens, Ranjana H. Advani, Brett Palmer, Barbara Pro, Reem Karmali, Eric Mou, Jeffrey Bearden, Gary Dillehay, Robert A. Bayer, Robert M. Eisner, Joan S. Chmiel, Kaitlyn O’Shea, Leo I. Gordon, Jane N. Winter

Blood (2021) 137 (10): 1318–1326.

https://doi.org/10.1182/blood.2020007400

Published: 2021

Includes: Supplemental data

Journal Articles

Hodgkin and Reed-Sternberg–like cells infected with human T-cell leukemia virus type 1

Yuma Tsuruta, Kennosuke Karube

Blood (2020) 136 (2): 257.

https://doi.org/10.1182/blood.2020005936

Published: 2020

Journal Articles

NLP Hodgkin lymphoma: can we get away with less?

Alison J. Moskowitz

Blood (2020) 135 (26): 2329–2330.

https://doi.org/10.1182/blood.2020005876

Published: 2020

Journal Articles

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

Blood (2020) 135 (10): 735–742.

https://doi.org/10.1182/blood.2019003127

Published: 2020

Includes: Supplemental data

Journal Articles

Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade

Bjoern Chapuy, Chip Stewart, Andrew J. Dunford, Jaegil Kim, Kirsty Wienand, Atanas Kamburov, Gabriel K. Griffin, Pei-Hsuan Chen, Ana Lako, Robert A. Redd, Claire M. Cote, Matthew D. Ducar, Aaron R. Thorner, Scott J. Rodig, Gad Getz, Margaret A. Shipp

Blood (2019) 134 (26): 2369–2382.

https://doi.org/10.1182/blood.2019002067

Published: 2019

Includes: Supplemental data

Journal Articles

The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4–positive T cells that are PD-1–negative

Sanjay S. Patel, Jason L. Weirather, Mikel Lipschitz, Ana Lako, Pei-Hsuan Chen, Gabriel K. Griffin, Philippe Armand, Margaret A. Shipp, Scott J. Rodig

Blood (2019) 134 (23): 2059–2069.

https://doi.org/10.1182/blood.2019002206

Published: 2019

Includes: Supplemental data

Journal Articles

Healthcare Resource Utilization and Costs in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A U.S. Real-World Observational Study

Xiaoqin Yang, François Laliberté, Guillaume Germain, MSc, Monika Raut, Mei Sheng Duh, Shuvayu S Sen, Dominique Lejeune, Kaushal D Desai, Philippe Armand

Blood (2019) 134 (Supplement_1): 2133.

https://doi.org/10.1182/blood-2019-128368

Published: 2019

Journal Articles

Late Effects Are Important Considerations in Initial Hodgkin Lymphoma Treatment Decision-Making According to Survivors

Anita J Kumar, MDMS, Rachel Murphy-Banks, MA, Ruth Ann Weidner, MBA, MRP, Susan K Parsons, MD MRP

Blood (2019) 134 (Supplement_1): 2137.

https://doi.org/10.1182/blood-2019-124481

Published: 2019

Journal Articles

Comparison of Health Outcomes in Adolescent and Young Adults (AYA) Oncology Patients Treated at a Pediatric Versus Adult Institute

Amy Moskop, MD, Ke Yan, PhD, Sarah K. Dobrozsi, MD, Julie Panepinto, MDMSPH

Blood (2019) 134 (Supplement_1): 4743.

https://doi.org/10.1182/blood-2019-121616

Published: 2019

Journal Articles

Resource Utilization and Costs in the Care of Patients with Hematologic Malignancies

Yi Ying Regina Li, MD, Soo Jin Seung, Stephanie Y Cheng, Matthew Cheung, MDMSc, Nicole Mittman, PhD MSc

Blood (2019) 134 (Supplement_1): 4745.

https://doi.org/10.1182/blood-2019-131407

Published: 2019

Journal Articles

Core Biopsies Performed By Experienced Radiologists and Analysed By Expert Haemato-Pathologists Reliably Permit the Rapid and Safe Diagnosis of Lymphoproliferative Diseases and Negate the Need for Excisional Biopsy in Almost All Patients. Experience from 554 Sequential Core Biopsies from a Single Centre

Oliver C Cohen, MBBS, BSc, FRCPath, Max Brodermann, Aoife Dervin, MBBS, BSc, MRCP, Simon Morley, Ian Proctor, Neel Raja, Kirit M. Ardeshna, MA, MD FRCP, FRCPath, William Townsend, MD FRCPath

Blood (2019) 134 (Supplement_1): 4746.

https://doi.org/10.1182/blood-2019-123698

Published: 2019

Journal Articles

Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the United States

François Laliberté, Monika Raut, Xiaoqin Yang, Guillaume Germain, MSc, Shuvayu S Sen, Sean D. MacKnight, Kaushal D Desai, Mei Sheng Duh

Blood (2019) 134 (Supplement_1): 4720.

https://doi.org/10.1182/blood-2019-128876

Published: 2019

Journal Articles

Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma

Alex F. Herrera, MD, Lu Chen, PhD, Leslie L. Popplewell, MD FRCPA, Lihua E Budde, MD PhD, Matthew Mei, MD, Saro H. Armenian, DO, MPH, Justin Darrah, MD, Liana Nikolaenko, MD, Robert W. Chen, MD, Lacolle Peters, Neena Kennedy, Steven Rosen, MD, Stephen J Forman, MD, Larry W Kwak, MD PhD

Blood (2019) 134 (Supplement_1): 759.

https://doi.org/10.1182/blood-2019-123163

Published: 2019

Journal Articles

Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort

Reid W Merryman, MD, Luca Castagna, MD, Paolo Corradini, MD, Vincent T. Ho, MD, David A. Bond, MD, Samantha Jaglowski, MDMPH, Michael A Spinner, Sally Arai, MD, Robert Lowsky, MD, Alex F. Herrera, MD, Anna Guidetti, MD, Geoffrey Shouse, DO, PhD, Didier Blaise, MD PhD, Jean Marc Schiano De Colella, MD, Talha Badar, MD, Mehdi Hamadani, MD, Stephen M Ansell, MD PhD, Yago Nieto, MD PhD, Chloe Spilleboudt, MD, Tatyana A. Feldman, MD, Lori Dahncke, BSN, Anurag K. Singh, MD, Joseph P. McGuirk, DO, Mohamad Mohty, MD PhD, Remy Dulery, MD, Aspasia Stamatoulas Bastard, Roch Houot, MD PhD, Guillaume Manson, MD, Marie-Pierre Moles, MD, Corentin Orvain, MD, Kamal Bouabdallah, MD, Matthew J. Frigault, MD, Yi-Bin Chen, Ryan C. Lynch, MD, Stephen D. Smith, MD, Uttam Rao, MD, Michael T Byrne, DO, Jason Romancik, MD, Jonathon B. Cohen, MDMS, Robin M. Joyce, MD, Maryam Rahimian, MD, Asad Bashey, MD PhD, Hatcher J. Ballard, BS, Jakub Svoboda, MD, Laura Giordano, Valter Torri, Beatrice Casadei, MD, Martina Sollini, MD, Chiara De Philippis, MD, Massimo Magagnoli, MD, Armando Santoro, Philippe Armand, MD PhD, Pier Luigi Zinzani, MD PhD, Carmelo Carlo-Stella, MD

Blood (2019) 134 (Supplement_1): 775.

https://doi.org/10.1182/blood-2019-125039

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

How I incorporate novel agents into the treatment of classical Hodgkin lymphoma

Mutational landscape of gray zone lymphoma

Protect our children: Hodgkin lymphoma survivors

Subsequent neoplasms in pediatric Hodgkin lymphoma

Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children’s Oncology Group

PD-1 blockade for untreated Hodgkin lymphoma

Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma

Hodgkin and Reed-Sternberg–like cells infected with human T-cell leukemia virus type 1

NLP Hodgkin lymphoma: can we get away with less?

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade

The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4–positive T cells that are PD-1–negative

Healthcare Resource Utilization and Costs in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A U.S. Real-World Observational Study

Late Effects Are Important Considerations in Initial Hodgkin Lymphoma Treatment Decision-Making According to Survivors

Comparison of Health Outcomes in Adolescent and Young Adults (AYA) Oncology Patients Treated at a Pediatric Versus Adult Institute

Resource Utilization and Costs in the Care of Patients with Hematologic Malignancies

Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the United States

Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma

Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort

Email alerts

ASH Publications

American Society of Hematology